CMS In Brief

Latest news from the Medicare agency includes updates from the physician fee schedule and clinical laboratory fee schedule, an American Hospital Association lawsuit, and more.

In a CMS-commissioned report released Nov. 7, the HHS Office of Inspector General found that suppliers’ improper billing of beneficiaries for non-mail order diabetes test strips contributed to a 33% increase in non-mail order test strip claims in competitive bidding areas from 2010-2011. During the same time period, less expensive mail order supplies were found to have decreased by 71%. OIG discovered that for 20% of the 211 beneficiaries reviewed for the report, suppliers had improperly billed Medicare for the non-mail order diabetes test strips in 2011, whereas beneficiaries reported having received the less expensive mail order test strips. In addition, 23% of beneficiaries reviewed by OIG reported supplier activities – such as waiving their co-payments and sending them unsolicited testing supplies – that OIG determined to be inappropriate. While OIG made no recommendations in the report, it noted that this information could be useful to CMS as the agency prepares to implement the national mail order competition for diabetes suppliers as part of it its durable medical equipment, prosthetics/orthotics and supplies competitive bidding program, projected to begin in 2013.

CMS released estimated payment rates for three new Category 1 CPT codes – totaling $833 in aggregate – related to procedures using Abiomed Inc.’s Impella heart pump, the company...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Policy & Regulation

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By 

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

FDLI: Clinical Labs Face Uncertainty After Texas Court’s LDT Ruling

 
• By 

A Texas court's decision against US FDA regulation of lab-developed tests (LDTs) has introduced new uncertainties for clinical labs. Industry stakeholders are now worried about potential future regulations while also managing existing compliance requirements. Recent conference discussions underscored the complexities of FDA oversight.

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By 

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

Plans For Specific EU Orphan And Pediatric Device Expert Panel Need To Go Further

 

Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.

More from Medtech Insight

Edwards Lifesciences Holds 2025 EPS Outlook Despite Tariff Headwind

 
• By 

The brunt of the tariff exposure stems from Singapore and Costa Rica, which together account for an estimated 70% to 80% of the tariff-related cost burden. Less than 10% of the exposure is tied to China.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By 

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.